Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,349 public trials 535 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Recruiting

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

NCT07166094

Conditions
Disease Attributes, Endometrial Cancer, Endometrial Neoplasms, +15 more
Locations
  • HonorHealth Research Inst Phoenix, Arizona, United States
  • Kaiser Permanente SoCal Irvine, California, United States
  • MedStar Washington Hospital Washington D.C., District of Columbia, United States
  • SMH - Sarasota - Main Campus Sarasota, Florida, United States
View all 171 locations
View Trial Details
Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

NCT06393738

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • Clinical Trial Site New Haven, Connecticut, United States
  • Clinical Trial Site Detroit, Michigan, United States
  • Clinical Trial Site New Brunswick, New Jersey, United States
  • Clinical Trial Site New York, United States
View all 21 locations
View Trial Details
Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

NCT07479797

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Duarte, California, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta Newnan, Georgia, United States
View all 19 locations
View Trial Details
Recruiting

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

NCT06846606

Conditions
Bone Marrow Diseases, Disease Attributes, Hematologic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Recruiting

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

NCT07637578

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Willamette Valley Cancer Institute and Research Center Eugene, Oregon, United States
  • SCRI Oncology Partners Nashville, Tennessee, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
View Trial Details
Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

NCT07082803

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Stanford Medicine Cancer Center Palo Alto, California, United States
  • The START Center for Cancer Care - Midwest Grand Rapids, Michigan, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View all 14 locations
View Trial Details
Recruiting

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +20 more
Locations
  • O'Neal Comprehensive Cancer Center, University of Alabama Birmingham, Alabama, United States
  • City of Hope - Phoenix Goodyear, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 32 locations
View Trial Details
Recruiting

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT07104032

Conditions
Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, +2 more
Locations
  • Mayo Clinic Cancer Center Phoenix, Arizona, United States
  • HonorHealth Cancer Center Scottsdale, Arizona, United States
  • Providence Medical Foundation Fullerton, California, United States
  • UC Irvine Health Orange, California, United States
View all 33 locations
View Trial Details

Related conditions